Literature DB >> 8932852

A comparison of early and late vaccination with Haemophilus influenzae type b conjugate and pneumococcal polysaccharide vaccines after allogeneic BMT.

T Parkkali1, H Käyhty, T Ruutu, L Volin, J Eskola, P Ruutu.   

Abstract

Forty-five adult allogeneic BMT recipients were randomized to receive Haemophilus influenzae type b (Hib)-diphtheria toxoid conjugate vaccine (PRP-D) at 6 and pneumococcal polysaccharide vaccine (Pnc PS) at 8 months (early group; n = 23) or at 18 and 20 months (late group; n = 22) after BMT, respectively. Serum antibody concentrations against Hib and Pnc PS types with varying immunogenicity (serotypes 3, 6B, and 19F) were measured by ELISA. The responses at 1 month after vaccination with PRP-D and Pnc PS were poor and similar in the two vaccination groups, except that two-fold responses in the concentration of antibodies to the most immunogenic Pnc serotype 3 occurred more frequently in the late group. In the late group recipients, the antibody responses elicited by Pnc serotypes 3 and 19F correlated with the concentrations of the corresponding antibodies in the donor. This study on allogeneic BMT recipients shows that vaccination at 6-8 months after BMT with one dose of PRP-D and Pnc PS vaccine is as immunogenic as vaccination at 18-20 months after BMT, and suggests that donor immunity to Pnc PS affects recipient responses to Pnc PS vaccination. Consequently, as among allogeneic BMT recipients the greatest risk for infections by encapsulated bacteria occurs during the first 1-2 years after BMT, Hib and Pnc vaccines should not be given later than 6-8 months post-BMT.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8932852

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  9 in total

1.  Immunization for bone marrow transplant recipients.

Authors:  B Lynn Johnston; John M Conly
Journal:  Can J Infect Dis       Date:  2002-11

2.  Immunization with Haemophilus influenzae type b conjugate vaccine in children given bone marrow transplantation: comparison with healthy age-matched controls.

Authors:  M A Avanzini; A M Carrà; R Maccario; M Zecca; G Zecca; A Pession; P Comoli; M Bozzola; A Prete; R Esposito; F Bonetti; F Locatelli
Journal:  J Clin Immunol       Date:  1998-05       Impact factor: 8.317

3.  Immunization of children receiving immunosuppressive therapy for cancer or hematopoietic stem cell transplantation.

Authors:  Avinash K Shetty; Mary A Winter
Journal:  Ochsner J       Date:  2012

4.  Response to pneumococcal (PNCRM7) and haemophilus influenzae conjugate vaccines (HIB) in pediatric and adult recipients of an allogeneic hematopoietic cell transplantation (alloHCT).

Authors:  Mary Pao; Esperanza B Papadopoulos; Joanne Chou; Heller Glenn; Hugo Castro-Malaspina; Ann A Jakubowski; Nancy A Kernan; Miguel A Perales; Susan Prokop; Andromachi Scaradavou; Marcel R vanDenBrink; James W Young; Richard J O'Reilly; Trudy N Small
Journal:  Biol Blood Marrow Transplant       Date:  2008-09       Impact factor: 5.742

5.  Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma.

Authors:  J D Robertson; K Nagesh; S N Jowitt; M Dougal; H Anderson; K Mutton; M Zambon; J H Scarffe
Journal:  Br J Cancer       Date:  2000-04       Impact factor: 7.640

Review 6.  Influenza and Pneumococcal Vaccination in Hematological Malignancies: a Systematic Review of Efficacy, Effectiveness, and Safety.

Authors:  Giuseppe La Torre; Alice Mannocci; Vittoria Colamesta; Valeria D'Egidio; Cristina Sestili; Antonietta Spadea
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-09-01       Impact factor: 2.576

Review 7.  Immune defects in the risk of infection and response to vaccination in monoclonal gammopathy of undetermined significance and multiple myeloma.

Authors:  Sarah M Tete; Marc Bijl; Surinder S Sahota; Nicolaas A Bos
Journal:  Front Immunol       Date:  2014-06-03       Impact factor: 7.561

8.  Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016.

Authors:  Andrew J Ullmann; Martin Schmidt-Hieber; Hartmut Bertz; Werner J Heinz; Michael Kiehl; William Krüger; Sabine Mousset; Stefan Neuburger; Silke Neumann; Olaf Penack; Gerda Silling; Jörg Janne Vehreschild; Hermann Einsele; Georg Maschmeyer
Journal:  Ann Hematol       Date:  2016-06-24       Impact factor: 3.673

9. 

Authors:  Hans-Jürgen Laws; Ulrich Baumann; Christian Bogdan; Gerd Burchard; Maximilian Christopeit; Jane Hecht; Ulrich Heininger; Inken Hilgendorf; Winfried Kern; Kerstin Kling; Guido Kobbe; Wiebe Külper; Thomas Lehrnbecher; Roland Meisel; Arne Simon; Andrew Ullmann; Maike de Wit; Fred Zepp
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2020-05       Impact factor: 1.513

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.